Pfizer - BioNTech COVID-19 Vaccine Recommended For Full Approval In EU

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for their COVID-19 Vaccine COMIRNATY to Full Marketing Authorization for all authorized indications and formulations.

The recommendation applies to all indications and formulations in the European Union, including COMIRNATY Original/Omicron BA.4-5 and COMIRNATY Original/Omicron BA.1 bivalent vaccines.

The European Commission will review the CHMP recommendation and is soon expected to make a final decision.

In a separate action, the CHMP also recommended approval for COMIRNATY as a 10-microgram booster (third) dose given at least six months after completion of a primary series for children 5 through 11 years of age. COMIRNATY 10- microgram was authorized in the EU in November 2021 as a two-dose primary series for children 5 through 11 years of age.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
Follow RTT